Phase II study of imatinib mesylate [Imatinib] plus hydroxyurea [hydroxycarbamide] in the treatment of patients with recurrent/progressive grade II low grade glioma.
Phase of Trial: Phase II
Latest Information Update: 14 Mar 2013
At a glance
- Drugs Hydroxycarbamide (Primary) ; Imatinib (Primary)
- Indications Glioma
- Focus Therapeutic Use
- 14 Mar 2013 Actual end date changed from Oct 2011 to Jun 2012 as reported by ClinicalTrials.gov.
- 19 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 24 Nov 2008 Status changed from recruiting to active, no longer recruiting, reported by ClinicalTrials.gov.